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ABSTRACT
Objectives: To assess the feasibility of a novel
diagnostic algorithm targeting patients with risk factors
for chronic liver disease in a community setting.
Design: Prospective cross-sectional study.
Setting: Two primary care practices (adult patient
population 10 479) in Nottingham, UK.
Participants: Adult patients (aged 18 years or over)
fulfilling one or more selected risk factors for
developing chronic liver disease: (1) hazardous alcohol
use, (2) type 2 diabetes or (3) persistently elevated
alanine aminotransferase (ALT) liver function enzyme
with negative serology.
Interventions: A serial biomarker algorithm,
using a simple blood-based marker (aspartate
aminotransferase:ALT ratio for hazardous alcohol
users, BARD score for other risk groups) and
subsequently liver stiffness measurement using
transient elastography (TE).
Main outcome measures: Diagnosis of clinically
significant liver disease (defined as liver stiffness
≥8 kPa); definitive diagnosis of liver cirrhosis.
Results: We identified 920 patients with the defined
risk factors of whom 504 patients agreed to undergo
investigation. A normal blood biomarker was found in
62 patients (12.3%) who required no further
investigation. Subsequently, 378 patients agreed to
undergo TE, of whom 98 (26.8% of valid scans) had
elevated liver stiffness. Importantly, 71/98 (72.4%)
patients with elevated liver stiffness had normal liver
enzymes and would be missed by traditional
investigation algorithms. We identified 11 new
patients with definite cirrhosis, representing a 140%
increase in the number of diagnosed cases in this
population.
Conclusions: A non-invasive liver investigation
algorithm based in a community setting is feasible
to implement. Targeting risk factors using a non-
invasive biomarker approach identified a substantial
number of patients with previously undetected
cirrhosis.
Trial registration number: The diagnostic algorithm
utilised for this study can be found on clinicaltrials.gov
(NCT02037867), and is part of a continuing
longitudinal cohort study.
INTRODUCTION
Current strategies to identify liver disease in
the general population rely on the use of
liver function enzyme blood tests, which are
non-speciﬁc markers of liver injury. In the
Strengths and limitations of this study
▪ The current study provides an alternative diag-
nostic algorithm to the usual flawed concept of
investigating patients for liver disease on the
basis of elevated liver function enzymes. We
introduced a novel algorithm that targets estab-
lished risk factors for chronic liver disease in a
primary care setting. Patients were investigated
utilising simple and cheap blood-based biomar-
kers followed by transient elastography (a vali-
dated biomarker of liver fibrosis).
▪ Patients with common lifestyle-related risk factors
for chronic liver disease (including hazardous
alcohol use and type 2 diabetes) were identified
using a widely utilised prospective primary care
database in the UK, from two general practices with
an adult population of 10 479 patients. Our patient
selection method, and subsequent investigation
algorithm, would therefore be easy to adopt at
other primary care sites in the UK.
▪ Further study is required in a number of areas to
address limitations of the current study, includ-
ing validation of the diagnostic algorithm in
other regions of the UK, investigation using alter-
native simple fibrosis markers or transient elasto-
graphy and health-economic analysis of earlier
identification of chronic liver disease.
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UK, persistently elevated liver enzymes typically trigger
referral to hospital-based gastroenterology and hepatol-
ogy clinics, where liver biopsy is the reference standard
investigation for staging of hepatic ﬁbrosis. This is an
inadequate strategy, as the absence of symptoms in early
stages of liver disease, and poor sensitivity of liver func-
tion blood tests to detect hepatic ﬁbrosis, often result in
late diagnosis. A recent study using data from a large
community database, the clinical practice research data-
link, suggested that 50% of patients with cirrhosis are
given their initial diagnosis of liver disease after the ﬁrst
hospitalisation with decompensation, which substantially
impaired prognosis independent of stage of cirrhosis,
versus patients who are diagnosed while ambulatory
(HR=2.78, 95% CI 2.53 to 3.06).1 By contrast, many
patients referred for investigation of abnormal liver tests
have no evidence of signiﬁcant liver disease when investi-
gated in hospital. A large study from Tayside, Scotland,2
has shown that at least 25% of a community population
will have their liver function tests (LFTs) checked in a
decade and around a third will have at least one abnor-
mal value. While abnormal transaminases were predictive
of liver disease (HR=4.2), the actual rate of detection was
very low with only 3.9% of those with abnormal transami-
nases being diagnosed with liver disease within 5 years of
the abnormal test. Subsequently, the BALLETS study3 has
shown convincing evidence that most abnormal LFTs in
primary care are due to non-alcoholic fatty liver disease
(NAFLD) or alcohol, and the yield for detecting other
parenchymal liver disease was only 3%.
These inefﬁcient diagnostic algorithms have contribu-
ted to the fact that liver-related deaths have continued
to rise in the UK,4 in stark contrast to other major
causes of death.5 Liver cirrhosis is now the third com-
monest cause of premature death (persons aged less
than 55 years).5 Given the majority of chronic liver
disease results from lifestyle-related risk factors that are
amenable to intervention, many deaths from chronic
liver disease are preventable. In order to tackle the
rising cirrhosis prevalence and mortality, we need an
investigation strategy that results in early detection of
hepatic ﬁbrosis while patients are still asymptomatic, and
which is both economically efﬁcient and acceptable to
patients. Targeting risk factors for chronic liver disease
rather than abnormal blood tests alone, performed
directly in a community setting, is one such approach
that is fundamentally different to current diagnostic
pathways. In a community setting, liver biopsy is not a
practical reference standard for liver disease stratiﬁca-
tion as it is invasive and requires specialist provision.6
Numerous non-invasive alternatives to liver biopsy for
ﬁbrosis staging have been validated in hospital popula-
tions, but require further evaluation in primary care
before widespread adoption into investigation algo-
rithms for the general population.
Despite the widespread recognition that signiﬁcant
liver disease exists in the context of normal LFTs,
current management algorithms are still dependent on
abnormal liver enzymes to initiate investigation. Our aim
was to challenge this ﬂawed concept by testing the feasi-
bility of a novel diagnostic algorithm that directly tar-
geted risk groups (including alcohol and diabetes),
rather than relying on LFTs. Importantly, we designed a
pathway that integrated non-invasive diagnostic tests and
liver specialists within a community setting. The pathway
used simple tests followed by a validated test of liver
ﬁbrosis (transient elastography, TE). We hypothesised
this approach would detect a substantial number of hith-
erto undiagnosed cases of chronic liver disease.
MATERIALS AND METHODS
Study setting
This was a prospective study with recruitment from two
suburban general medical practices in Rushcliffe,
Nottingham, UK (the least deprived borough in
Nottingham), with a total patient population of 12 368.
The study ran for 14 months from February 2012 to
April 2013; local regulatory approval was obtained (10/
HO405/8 and 13/EM/0123), and written informed
consent was gained from patients. Both practices utilise
the SystmOne general practice records system (TPP, UK)
for live recording of clinical, anthropometric and bio-
chemical patient data. Data are stored as searchable
numeric data or prospectively coded with ‘Read codes’
(clinical encoding of numerous parameters including
patient demographics, diagnoses, clinical signs and
laboratory test results).
Study patient selection
From the electronic general practice records, we identi-
ﬁed adult patients (aged 18 years or older) with selected
risk factors for lifestyle-related chronic liver disease at
the start of the study period. Patients were eligible for
study inclusion regardless of previous liver function
blood test results, if identiﬁed with one or more of the
following chronic liver disease risk factors:
A. Hazardous alcohol use—deﬁned as >14 units per
week ethanol consumption for women and >21 units
per week ethanol consumption for men, or alcohol
AUDIT questionnaire score ≥8, or presence of Read
codes related to alcohol misuse.
B. Type 2 diabetes—presence of Read codes related to
type 2 diabetes (a full code list is available from the
authors on request).
C. Raised alanine aminotransferase (ALT)—as a com-
parator group, patients with persistently elevated
serum ALT levels (deﬁned as ≥2 consecutive occa-
sions above local laboratory cut-offs) without type 2
diabetes or hazardous alcohol use were assessed. In
order to ensure only patients with alcohol-related
liver disease or NAFLD were investigated, other
causes of chronic liver disease were excluded by spe-
ciﬁc testing of chronic viral hepatitis B and C, auto-
immune liver diseases, haemochromatosis and
common genetic liver diseases, and no other relevant
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reason for transaminase elevation (eg, congestive
cardiac failure, medication use). Local laboratory
cut-offs denoting elevated ALT are >35 U/L for
women and >45 U/L for men.
Identiﬁed patients were excluded from the study a
priori if: (1) there was deﬁnitive evidence of hepatic
ﬁbrosis or cirrhosis from previous investigation, (2)
there was a contraindication to TE (pregnancy, indwel-
ling cardiac device) or (3) patients were unable to
consent to investigation, or were housebound and could
not attend the community practice.
Diagnostic algorithm
Patients identiﬁed with the deﬁned risk factors were
invited to the diagnostic algorithm (see ﬁgure 1).
Patients with type 2 diabetes were invited opportunistic-
ally at their diabetes annual review. Patients with hazard-
ous alcohol use were invited opportunistically during
primary care appointments or via letter where they did
not undergo a consultation during the study period.
Patients in the raised ALT subgroup were prospectively
referred by the investigating general practitioner (GP).
Patients initially underwent a simple blood-based bio-
marker, with a high negative predictive value to accur-
ately rule out hepatic ﬁbrosis and therefore avoid the
need for further tests. Hazardous alcohol users had the
aspartate aminotransferase (AST):ALT ratio measured, a
simple and cheap blood biomarker that has been shown
to reﬂect disease severity in a number of chronic liver
diseases, including alcoholic liver disease,7 autoimmune
liver disease8 and hepatitis C.9 As there are limited pub-
lished data on diagnostic thresholds of AST:ALT ratio
identifying alcohol-related liver ﬁbrosis, a conservative
AST:ALT cut-off of 0.8 was used to rule out hepatic
ﬁbrosis. Patients with type 2 diabetes or persistently
raised ALT had the BARD score,10 which is a simple
weighted score of body mass index (BMI) ≥28 kg/m2,
AST:ALT ratio ≥0.8 and type 2 diabetes, measured. A
BARD score of less than 2 in hospital populations of
NAFLD has a high negative predictive value to rule out
signiﬁcant hepatic ﬁbrosis.10–13 We therefore considered
that a score of ≥2 indicated an increased risk. Patients
with a normal simple biomarker test result did not
proceed down the algorithm.
Patients with a high simple biomarker result under-
went TE at the community practice. TE is a non-invasive
imaging method that calculates liver stiffness via meas-
urement of the propagation of an elastic shear wave
through the liver substance. TE accurately predicts liver
biopsy ﬁndings of ﬁbrosis and cirrhosis in all major aeti-
ologies of chronic liver disease.14 TE was performed by
one of three trained nurses, all of whom had performed
more than 50 examinations in the hospital prior to the
start of study, using the portable Fibroscan FS402 device
(Echosens, Paris). The technique for liver stiffness meas-
urement using elastography has been previously
described in detail.15 The median value of successful
measurements, measured in kilopascals (kPa) was repre-
sentative of liver stiffness. A scan failure was deﬁned as
the inability to obtain 10 valid elastography measure-
ments on a single patient. A successful TE result was
deemed unreliable if liver stiffness was ≥7.1 kPa and the
IQR/median was greater than 0.3 as per recent guid-
ance.16 17 Patients with a BMI of greater than 35 kg/m2
underwent TE at the hospital using the XL probe
(FS502 device), due to high rate of scan failures using
the standard M probe above this BMI threshold.18 All
patients, regardless of TE threshold result, received
Figure 1 Diagnostic algorithm
and patient flow chart through
non-invasive biomarker pathway.
ALT, alanine aminotransferase,
AST, aspartate aminotransferase;
GP, general practitioner; TE,
transient elastography.
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lifestyle advice from the nurses and were given the
British Liver Trust ‘Looking After Your Liver’ leaﬂet.
A TE threshold of 8.0 kPa or greater, which has been
previously shown to accurately determine presence of
hepatic ﬁbrosis during community screening,19 was used
to deﬁne elevated liver stiffness, and hence clinically sig-
niﬁcant liver disease. Patients with high liver stiffness
results, including high but unreliable acquisitions, were
reviewed by a visiting consultant hepatologist in the com-
munity. Where appropriate, further investigations includ-
ing ultrasonography, liver biopsy and enrolment into
cirrhosis surveillance programmes, were organised after
this consultation. Cirrhosis was deﬁnitively diagnosed in
all cases based on established clinical, radiological
(including TE result) and/or histological assessment.
Local cut-offs for elevated ALT (>35 U/L for women
and >45 U/L for men), suggested alternative cut-offs
from the literature20 (>19 U/L for women and >30 U/L
for men), and simple serum ﬁbrosis scores AST:platelet
ratio index (APRI) (>1.5)21 and FIB4 (>3.25)22 were
compared for identifying elevated liver stiffness and cir-
rhosis in the study population.
Statistics
Statistical analysis was performed using SPSS V.19.0
(IBM). Categorical data are presented as numbers (per-
centage). Continuous data are presented as mean (SD)
for parametric data and medians (range) for non-
parametric data. Anthropometric and biochemical data
were compared between patients with normal and ele-
vated liver stiffness—continuous variables were com-
pared using the two sample t test for parametric
variables and Mann-Whitney test for non-parametric
variables. Categorical variables were compared using χ2
test, or Fisher’s exact test where appropriate.
RESULTS
Study population
The total patient population of the two participating
general medical practices was 12 368, of which 10 479
patients were adults. In total, 5922 adult patients
(56.5%) had alcohol consumption documented, with
6.3% of the total GP population (658 patients) meeting
our deﬁnition for hazardous alcohol use. The adult
prevalence of type 2 diabetes was 3.7% (390 patients).
Both of these risk factors were found in 21 patients and
thus 1027 patients were identiﬁed for the study. We
excluded 107 patients and therefore 920 were invited to
the study (see ﬁgure 1). Of the excluded patients eight
had prior deﬁnitive staging of liver disease due to
alcohol (3 patients), hepatitis B (2), non-alcoholic stea-
tohepatitis (NASH; 1), haemochromatosis (1) and
primary biliary cirrhosis (1). Overall, 504 patients
(54.8%) underwent the simple blood-based biomarker;
the baseline characteristics for these patients compared
with all adult patients in the primary care practices are
shown in table 1. Patients who underwent the simple
blood-based biomarker were older than the comparative
total adult primary care population, and were more
likely to be male, obese and have ischaemic heart
disease. Compared with the 416 patients who did not
undergo liver disease screening, the 504 attenders were
signiﬁcantly older (mean age 60.4 vs 40.3 years;
p<0.001), but gender was no different (male gender
69.8% vs 69.8%; p=1.00).
Blood test uptake differed signiﬁcantly between
patients with type 2 diabetes and hazardous alcohol
users (91.4% vs 37.6%, p<0.001). Normal blood-based
biomarker results were seen in 62 patients (12.3%). In
total, 378 patients underwent TE, of whom portable
M-probe readings were performed in 361 patients
(95.5%), while XL probe readings were performed in
the remaining 17 patients. It was not possible to obtain a
valid liver stiffness measurement in 12 patients (3.2%),
and a further 24 patients (6.3%) had an unreliable
measurement.
Chronic liver disease risk factors in those with raised
blood-based biomarkers
Hazardous alcohol use was present in 174 patients
(46.0%), type 2 diabetes in 211 patients (55.8%) and
raised ALT in 54 patients (14.3%; includes 13 patients
without hazardous alcohol use or type 2 diabetes).
Table 1 Baseline characteristics of all adult patients at
studied general practice sites compared with patients
undergoing study
Variable
All adult
GP patients
(n=10 479)
Patients
undergoing
study*
(n=504) p Value
Age, n (%) (years)
18–30 2100 (20.4) 20 (4.0) <0.001
31–40 2469 (23.6) 45 (8.9) <0.001
41–50 1903 (18.2) 66 (13.1) 0.005
51–60 1331 (12.7) 94 (18.7) <0.001
61–70 1287 (12.3) 131 (26.0) <0.001
71–80 781 (7.5) 103 (20.4) <0.001
>80 608 (5.8) 45 (8.9) 0.005
Male gender, n (%) 5131 (49.0) 352 (69.8) <0.001
Body mass index, n (%)
25–29.9 2835 (27.1) 201 (39.9) <0.001
≥30 1320 (12.6) 160 (31.7) <0.001
Missing 1363 (13.0) 17 (3.4) <0.001
Hazardous alcohol
use, n (%)
658 (6.3) 247 (49.0) <0.001
Type 2 diabetes, n (%) 390 (3.7) 276 (54.8) <0.001
Ischaemic heart
disease, n (%)
423 (4.0) 65 (12.9) <0.001
Hypertension, n (%) 1521 (14.5) 215 (42.7) <0.001
Hyperlipidaemia, n (%) 2117 (20.2) 310 (61.5) <0.001
*Patients undergoing study refers to all patients having the simple
blood biomarker step of stratification. Categorical variables are
displayed as n (%) and compared using χ2 test.
p Values reaching statistical significance (p≤0.05) are shown in
bold.
GP, general practitioner.
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Overall, 57 patients (15.1%) had more than one chronic
liver disease risk factor (see ﬁgure 2). Baseline character-
istics for all patients undergoing TE and the individual
risk factor groups are shown in table 2.
Significant liver disease detection
Valid liver stiffness acquisition was possible in 366
patients (96.8%). A new diagnosis of clinically signiﬁcant
liver disease was made in 98 patients (26.8%) with valid
TE measurement. This represents a substantial increase
in diagnoses for these practices. A signiﬁcantly greater
percentage of patients with type 2 diabetes had elevated
liver stiffness compared with hazardous alcohol users
(34.0% vs 18.3%, p≤0.001; ﬁgure 3). Patients with more
than one deﬁned risk factor (n=53 with successful TE
measurement) had a signiﬁcantly greater percentage of
elevated liver stiffness compared with patients with type
2 diabetes alone (49.1% vs 29.5%, p=0.01) or with
hazardous alcohol use alone (49.1% vs 14.1%, p<0.001).
In the subgroup of patients with raised ALT but neither
hazardous alcohol use nor type 2 diabetes (ﬁgure 2),
elevated liver stiffness was observed in 4/13 (30.8%)
patients with raised ALT but neither hazardous alcohol
use nor type 2 diabetes. A diagnosis of NASH with early
ﬁbrosis was assigned in all four cases.
Patients with elevated liver stiffness (n=98) were older,
had a higher BMI and higher prevalence of the meta-
bolic syndrome than those with normal liver stiffness
(n=268). On laboratory testing, patients with elevated
liver stiffness had lower platelet count, greater prevalence
of thrombocytopaenia, higher serum ALTand lower AST:
ALT ratio than patients with normal liver stiffness (see
online supplementary table S1). The simple serum ﬁbro-
sis scores for APRI and FIB4 were signiﬁcantly higher in
patients with elevated liver stiffness. However, these
markers were only elevated in 2.0% and 10.2% of patients
with elevated liver stiffness, respectively.
Of 98 patients referred for community assessment by
the hepatologists, liver biopsy was performed in 25
patients for whom there was diagnostic uncertainty on
review of clinical data and TE results. Median biopsy
length was 13 mm (IQR 7.5–18.0), and 12/25 patients
had cores ≥15 mm. Hepatic ﬁbrosis was conﬁrmed
in 20 patients undergoing liver biopsy; the remainder
all had steatohepatitis (see online supplementary
ﬁgure S1). Overall, 11 patients were newly diagnosed
with liver cirrhosis during the study period based on
clinical, radiological and/or histological assessment; 4
of these patients had additional evidence of portal
hypertension (see online supplementary table S2).
Prior to starting the study, only eight patients were
known to have cirrhosis in this primary care
Figure 2 Distribution of chronic liver disease risk factors for
all patients (n=378) undergoing transient elastography
examination (ALT, alanine aminotransferase).
Table 2 Baseline population characteristics of 378 patients with raised blood biomarker result undergoing TE
Variable
All patients
undergoing
TE (n=378)
Hazardous
alcohol use*
(n=174)
Type 2
diabetes*
(n=211)
Raised ALT*
(any case)
(n=54)
Age, years 61.8 (15.0) 54.8 (14.9) 68.5 (11.3) 57.0 (11.5)
Male, n (%) 255 (67.5) 138 (79.3) 130 (61.6) 32 (59.3)
Body mass index, kg/m2 28.53 (5.25) 26.5 (4.2) 30.0 (5.2) 31.1 (5.7)
Obesity, n (%) 130 (34.4) 32 (18.4) 100 (47.4) 29 (53.7)
Hypertension, n (%) 173 (45.8) 47 (27.0) 134 (63.5) 23 (42.6)
Metabolic syndrome, n (%) 117 (31.0) 18 (10.3) 105 (49.8) 24 (44.4)
Ischaemic heart disease, n (%) 53 (14.0) 11 (6.3) 44 (20.9) 7 (13.0)
Type 2 diabetes, n (%) 211 (55.8) 20 (5.7) 211 (100) 27 (50.0)
Hazardous alcohol use, n (%) 174 (46.0) 174 (100) 20 (9.5) 18 (33.3)
Platelets, 109/L 240.66 (62.45) 240.2 (54.8) 239.6 (65.0) 240.2 (64.6)
Creatinine, µmol/L 90.21 (23.65) 87.7 (20.8) 92.9 (27.9) 85.2 (15.0)
Bilirubin, µmol/L 11.97 (5.04) 12.4 (4.4) 11.7 (5.3) 11.2 (6.2)
Albumin, g/L 37.78 (2.92) 38.2 (2.9) 37.5 (3.0) 38.0 (2.8)
ALT, IU/L 28.09 (19.06) 28.4 (21.4) 27.2 (15.7) 60.4 (30.6)
AST, IU/L 27.91 (18.97) 30.7 (24.6) 25.0 (11.0) 52.0 (39.6)
AST:ALT ratio 1.09 (0.36) 1.16 (0.35) 1.03 (0.37) 0.86 (0.24)
Numerical variables are displayed as mean (SD), categorical variables are displayed as n (%).
*Patient numbers refer to patients fulfilling the single risk factor alone (see figure 2).
ALT, alanine aminotransferase, AST, aspartate aminotransferase; TE, transient elastography.
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population. The new observed cirrhosis prevalence of
19 patients after the study period therefore represents
a 140% increase compared with before the study;
usual care methods missed the majority of patients
with very advanced liver disease.
For local ALT cut-offs (>35 U/L for women and
>45 U/L for men), 72.4% of patients with elevated liver
stiffness, 60% with liver ﬁbrosis on biopsy and 90.9%
with liver cirrhosis had normal ALT levels, and would
have been missed by standard diagnostic algorithms.
Using conservative cut-offs (>19 U/L for women and
>30 U/L for men) would still have missed 41.8% of
patients with elevated liver stiffness and 18.2% with cir-
rhosis (see table 3). Simple serum score thresholds of
APRI >1.5 and FIB4 >3.25 would have detected 0 and 2
(18.2%) patients with cirrhosis, respectively.
DISCUSSION
Statement of principal findings
This study uses a novel approach to detect clinically sig-
niﬁcant but asymptomatic chronic liver disease, based
on: (A) directly targeting established risk factors and not
simply using LFTs and (B) the integration of validated
non-invasive tests of liver ﬁbrosis and liver specialists
within a community setting. The utilisation of a simple,
low-cost algorithm detected a large number of previously
undiscovered subclinical but signiﬁcant chronic liver
disease cases, including 98 patients with elevated liver
stiffness (26.8% of all those with successful liver stiffness
measurements), and the number of observed cases of
liver cirrhosis in the primary care population of 10 479
adult patients from which our high-risk patients were
drawn was increased by 140% compared with before the
study. The study highlights the inadequacy of liver func-
tion enzymes as a stratiﬁcation tool in primary care: 72%
of patients with elevated liver stiffness, 60% with liver
ﬁbrosis on biopsy and 91% diagnosed with cirrhosis had
normal ALT. In the absence of liver function abnormal-
ities, or speciﬁc liver-related symptoms, their disease
would have been missed by the standard diagnostic algo-
rithms. We have demonstrated this diagnostic approach
is feasible to implement and acceptable to patients, with
more than 95% of investigations occurring in the com-
munity setting and non-attendance rates for TE appoint-
ments of less than 5%. This nurse-led TE service, which
Figure 3 Transient elastography
results of patients with successful
liver stiffness acquisition (n=366)
(ALT, alanine aminotransferase).
Table 3 Serum alanine aminotransferase (ALT) levels of 366 patients with successful liver stiffness acquisition
Liver stratification
Raised ALT
local laboratory*
Normal ALT
local laboratory*
Raised ALT
19/30†
Normal ALT
19/30†
Normal liver stiffness (n=268) 26 (9.7%) 242 (90.3%) 88 (32.8%) 180 (67.2%)
Elevated liver stiffness (n=98) 27 (27.6%) 71 (72.4%) 57 (58.2%) 41 (41.8%)
Cirrhosis (n=11) 1 (9.1%) 10 (90.9%) 9 (81.8%) 2 (18.2%)
Serum ALT levels of 25 patients with elevated liver stiffness undergoing subsequent percutaneous liver biopsy
No hepatic fibrosis (n=5) 1 (20%) 4 (80%) 3 (60%) 2 (40%)
Any hepatic fibrosis (n=20) 8 (40%) 12 (60%) 15 (75%) 5 (25%)
Numerical values are displayed as n (%).
*Locally utilised cut-offs: ALT >35 IU/L for women and >45 IU/L for men.
†Alternative cut-offs: ALT >19 IU/L for women and >30 IU/L for men. Values are displayed as n (%) in all cases.
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we originally established in the hospital setting,23 has
now been implemented in the community with equiva-
lent quality assurance as evidenced by successful TE
acquisition in 96.8% and reliable measurements in
90.5% of cases.
Strengths and weaknesses of the study
This study is the ﬁrst to utilise blood biomarkers and TE
to stratify patients at risk of liver disease in a community
population of the UK. We have utilised a novel diagnos-
tic algorithm, which is rapidly applicable in clinical prac-
tice, in a large community population of more than
10 000 adults. Targeting patients with well-deﬁned risk
factors for liver disease resulted in a high pretest prob-
ability of detecting hepatic ﬁbrosis, with 26.8% of
patients with TE results exceeding the threshold for clin-
ically signiﬁcant liver disease. Of 25 patients undergoing
conﬁrmatory liver biopsy, 80% had histological evidence
of ﬁbrosis. It is possible to argue that the remaining
biopsies exposed patients to unnecessary risks of liver
biopsy, although these ﬁve patients had histological evi-
dence of steatohepatitis, suggesting a high risk of future
progression to hepatic ﬁbrosis or cirrhosis. This is a far
greater diagnostic yield than traditional algorithms using
elevated liver enzymes alone to stratify ﬁbrosis risk,2 3
and is likely therefore to be a cost-efﬁcient approach;
formal health-economic modelling studies are required
to conﬁrm this. The use of simple and inexpensive tests
as the initial diagnostic, followed by more specialist tests,
rationalised resource use and enhanced the feasibility of
stratifying the large community population. Moreover,
we extrapolated data from hospital-based studies and
used conservative thresholds for the diagnostic tests.
These prior studies demonstrated a high negative pre-
dictive value (≥93%)11 14 for ruling out signiﬁcant ﬁbro-
sis using our chosen ﬁbrosis markers. In a community
population, where the disease prevalence is lower than
prior hospital-based studies, we would expect their nega-
tive predictive value to be higher (albeit in exchange for
a reduction in positive predictive value). Thus, we
believe it is unlikely that we have missed signiﬁcant
disease within the risk groups that we have stratiﬁed.
However, long-term follow-up of these patients will be
necessary to conﬁrm this. As it is clear that the type of
risk factor and presence of multiple risk factors alter the
diagnostic yield, a further strength of the pathway is that
it can be applied to diverse risk factors, with either the
tests or thresholds adjusted depending on the initial risk
factor(s), and this improves the generalisability of our
pathway to other healthcare regions.
However, there are limitations to discuss from our
approach. We investigated patients from speciﬁc medical
practices within a distinct sociodemographic area of the
UK. It is possible that both patient attendance and the
detection of clinically signiﬁcant liver disease may differ
elsewhere, and further study of our algorithm in other
regions is necessary. The pragmatic study design, both in
terms of biomarker selection and investigation of
selected risk factors for liver disease, means we also
cannot formally assess the sensitivity of the algorithm, or
the total ﬁbrosis and cirrhosis prevalence, in this com-
munity population. Alcohol use was only screened in
57% of this community population, which is lower than
the approximately 70% documentation of alcohol intake
in primary care practices in the East Midlands region.24
We also cannot account for those patients who have
under-reported their alcohol intake to be within normal
limits. Furthermore, additional risk factors such as
obesity and the metabolic syndrome, while incorporated
partially in this pathway (eg, BARD score) were not spe-
ciﬁcally included, to ensure feasible stratiﬁcation of the
deﬁned at-risk patient groups during the time of the
study period. Taken together, the detected prevalence of
signiﬁcant disease, including cirrhosis, may represent an
underestimate and the presence of cirrhosis in the com-
munity is likely to be higher than we report. Also of
note, patient uptake of screening was not optimal (55%
of targeted patients were investigated with the algo-
rithm). However, this is comparable to uptake rates of
colorectal cancer screening,25 26 and greater than other
community liver disease stratiﬁcation studies, where
screening uptake is explicitly reported.27–29 In the UK,
patients with diabetes undergo an annual health check,
which made them more accessible for opportunistic invi-
tation for screening, and this is one explanation for this
signiﬁcant difference in uptake compared with patients
with hazardous alcohol use (91% vs 38% undergoing
investigation, respectively). Lastly, there is scope to
improve our diagnostic algorithm further. In total, only
12% of patients were excluded from TE by the simple
blood-based biomarkers. Future studies using alternative
simple serum ﬁbrosis tests, including APRI and FIB4,
compared with TE alone, are warranted to develop an
optimal signiﬁcant liver disease detection algorithm in
the community.
Strengths and limitations in relation to other studies
Previous studies of chronic liver disease stratiﬁcation in
the general population support our ﬁndings of an
appreciable burden of previously undetected chronic
liver disease. A study of presumed well army personnel
and families in the USA30 screened 328 participants with
ultrasound and liver biopsy for NAFLD. This approach
identiﬁed a high prevalence of both NASH (12.2%) and
signiﬁcant ﬁbrosis (2.7%). An alternative, non-invasive
approach using TE was employed to screen a deﬁned
general population for signiﬁcant liver disease in
France.19 TE was performed in 1358 asymptomatic
patients over the age of 45 from a well person clinic. An
elevated reading, above a validated threshold of 8 kPa,
was found in 7% of the cohort and nine cases of cirrho-
sis were detected. A further study of 7463 patients aged
over 40 years and investigated sequentially with Fibrotest
(a serum ﬁbrosis marker) and TE, detected a ﬁbrosis
prevalence of 2.8% and cirrhosis prevalence of 0.3%.31
Importantly, these prior studies used an unselected
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approach to detect liver disease in the community. We
deliberately focused our diagnostic tests on individuals
with risk factors for liver disease. The pretest probability
of detecting disease is increased using this approach and
this is evidenced by the fact that 26% of our cohort
undergoing TE had elevated liver stiffness readings com-
pared with 7% in the Roulot et al19 study. A risk factor in
combination with the elevated biomarker tests also ratio-
nalises the use of liver biopsy with a high yield of clinic-
ally signiﬁcant liver disease. In our study, the positive
predictive value of selected patients undergoing liver
biopsy was 80% for detecting any ﬁbrosis. This compares
favourably to the 18% positive predictive value of
ﬁnding any ﬁbrosis on biopsy following investigation of
raised liver enzymes in seronegative individuals.32
A recent study in the UK investigated 1118 patients
with elevated liver enzymes in primary care; in those
with suspected NAFLD, 7.6% were found to have signiﬁ-
cant disease based on an elevated NAFLD ﬁbrosis
score.3 An important ﬁnding from our study is that
normal ALT levels, within the local laboratory range,
were found in 72% of patients with elevated liver stiff-
ness and 91% of patients with cirrhosis. Thus, the reli-
ance on abnormal liver enzymes to detect chronic liver
disease, which represents standard clinical practice, is
inherently ﬂawed. In NAFLD, the presence of signiﬁcant
liver disease in the context of normal enzymes is well
documented. The entire spectrum of NAFLD severity
has been shown to exist in patients with normal liver
enzymes; multiple studies have observed no difference
in disease severity between this group and those with
abnormal liver enzymes.33–35 Interestingly, if more con-
servative thresholds are utilised in our population at the
19/30 U/L cut-off, as advocated by the work of Prati
et al,20 then a normal ALT is still observed in 42% of
individuals with elevated liver stiffness and in 18% of
those with cirrhosis. In those patients with an elevated
ALT, 13 patients (24%) did not have type 2 diabetes or
hazardous alcohol use as a comorbidity. Only 4 out of
these 13 patients had an abnormal TE reading. Thus,
our work strongly supports the concept that the risk for
chronic liver disease is better encapsulated by the under-
lying risk factor as opposed to liver enzyme tests alone.
Implications for clinicians and policymakers
The utilisation of a simple, low-cost and patient accept-
able algorithm in the community resulted in the detec-
tion of a large number of cases of previously unidentiﬁed
chronic liver disease. While the detection of these new
cases is currently of unproven beneﬁt, there are likely to
be a number of advantages. Early identiﬁcation of asymp-
tomatic liver disease is likely to reduce future liver-related
morbidity and mortality. Interventions for lifestyle-related
disease risk factors form established treatments (such as
brief interventions for alcohol, or dietary and exercise
advice), can be performed in a community setting36 37
and are cost-effective.38 39 A decision analysis study that
modelled early identiﬁcation of NAFLD and subsequent
lifestyle or medical intervention showed a 41% relative
risk reduction in liver-related mortality at 5 years, com-
pared with a strategy of not investigating these patients.40
Furthermore, detection of compensated cirrhosis while
patients are asymptomatic and ambulatory, with enrol-
ment into surveillance programmes, is of proven beneﬁt
to reduce mortality and morbidity,41–43 and also reduces
the expensive healthcare utilisation of the decompen-
sated state.
Second, early identiﬁcation of chronic liver disease is
likely to be cost-effective compared with traditional investi-
gation algorithms. The investigation of liver disease in spe-
cialist centres can be expensive for the healthcare system
and inconvenient to the patient. Recent economic model-
ling from the UK has suggested that the substitution of
elastography for liver biopsy in a hospital setting would
save £520 per patient investigated.44 Implementing these
services in the community is likely to improve the health-
economic beneﬁts of early liver disease detection yet
further, although future health-economic modelling
studies are required to conﬁrm this.
Lastly, there are no current medical treatments with
widely proven efﬁcacy to prevent ﬁbrosis progression in
either alcohol-related liver disease or NAFLD. Novel
investigation algorithms, such as the one we have pre-
sented, identify a representative population of patients
with clinically signiﬁcant liver disease in whom appropri-
ate therapies may be tested and developed. These, in
conjunction with wider adoption of health-related life-
style changes, may enable reduction of disease progres-
sion, symptomatic liver disease and liver disease-related
deaths at a general population level.
CONCLUSIONS
We have utilised a novel diagnostic approach in the
general population by identifying patients with chronic
liver disease risk factors and stratifying using non-
invasive ﬁbrosis biomarkers. This algorithm was feasible
to implement and resulted in increased detection of
asymptomatic but clinically signiﬁcant liver disease com-
pared to traditional liver enzyme-based algorithms,
including a 140% increase in observed cirrhosis preva-
lence. Importantly, the majority of patients diagnosed
with signiﬁcant liver disease had normal liver function
enzymes. Future studies are warranted to ensure the gen-
eralisability of our ﬁndings to other community popula-
tions, to identify the optimal biomarker algorithm for
detecting clinically signiﬁcant liver disease and, subse-
quently, the health-economic beneﬁts of this approach
compared with standard care.
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